The gene-editing treatment will be available to certain patients with sickle cell disease in England as Vertex commits to collecting additional data.

S hares of CRISPR Therapeutics CRSP have lost more than 30% in the past year. Though the stock soared at the onset of 2024, thanks to the FDA approval of its one-shot gene therapy Casgevy for two ...

Its efficacy is proven, but selling the treatment has been an uphill battle. Casgevy is essentially a vial of a patient's stem cells that have been edited outside their body to permanently produce ...